Study summary
A CGRP antibody infusion did not cut attacks in its main test
50.9%had attacks halved in week 2, vs 37.3% with placebo
What was tested
Eptinezumab, an IV CGRP antibody approved for migraine, against placebo at the start of an episodic cluster headache bout.
What they found
- Attacks in weeks 1 to 2 did not fall significantly more than with placebo.
- More people had their attacks halved (50.9% vs 37.3% in week 2).
What it means
Mixed result. CGRP drugs help some people with cluster headache, but less reliably than in migraine.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.